Literature DB >> 19508545

The efficacy of treatment of patients with severe constipation or recurrent pseudo-obstruction with pyridostigmine.

C J O'Dea1, J H Brookes, D A Wattchow.   

Abstract

OBJECTIVE: Disorders of colonic motility, such as severe constipation and pseudo-obstruction, remain difficult to treat. The pathophysiology of these conditions is not completely understood, but previous studies suggest a deficiency of cholinergic innervation and an imbalance in autonomic regulation of colonic motor function as contributing factors. Therefore, increasing the availability of acetylcholine in the bowel wall with a cholinesterase inhibitor, such as pyridostigmine, may improve symptoms.
METHOD: We studied thirteen patients with severe constipation (slow transit type) or recurrent pseudo-obstruction. The six patients with slow transit constipation had mechanical obstruction and pelvic floor dysfunction excluded, and normal calibre colon and slow transit confirmed. These patients were offered pyridostigmine in an attempt to avoid surgery. The seven patients with pseudo-obstruction had dilated bowel on imaging, and mechanical obstruction was excluded. These patients received pyridostigmine when symptoms recurred, despite previous treatments. Pyridostigmine was initiated at 10 mg b.i.d. and increased if required.
RESULTS: One of the six patients with slow transit constipation reported improvement of symptoms and had concurrently weaned anti-psychotic medications. Pyridostigmine was ceased in the remaining five patients due to lack of efficacy and/or side effects. Four patients proceeded to surgery for refractory symptoms. All seven patients with pseudo-obstruction had some improvement of symptoms with few side effects. Of these, two later had surgery for recurrent symptoms.
CONCLUSION: In patients with slow transit constipation, treatment with pyridostigmine does not improve symptoms. However, it does improve symptoms in patients with recurrent pseudo-obstruction with few side effects, offering an extra treatment option for these patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19508545     DOI: 10.1111/j.1463-1318.2009.01838.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  14 in total

1.  Clinical Features and Colonic Motor Disturbances in Chronic Megacolon in Adults.

Authors:  Ralph Hurley O'Dwyer; Andrés Acosta; Michael Camilleri; Duane Burton; Irene Busciglio; Adil E Bharucha
Journal:  Dig Dis Sci       Date:  2015-04-14       Impact factor: 3.199

Review 2.  Small Bowel Dysmotility, Pseudoobstruction, and Functional Correlation with Histopathology: Lessons Learned.

Authors:  Zorisadday Gonzalez; Richard McCallum
Journal:  Curr Gastroenterol Rep       Date:  2020-02-20

Review 3.  Acute Colonic Pseudo-Obstruction.

Authors:  Thomas Arthur; Adele Burgess
Journal:  Clin Colon Rectal Surg       Date:  2022-08-12

4.  Advances and challenges in the management of acute colonic pseudo-obstruction (ogilvie syndrome).

Authors:  Arpana Jain; H David Vargas
Journal:  Clin Colon Rectal Surg       Date:  2012-03

5.  Application of Pyridostigmine in Pediatric Gastrointestinal Motility Disorders: A Case Series.

Authors:  Mhd Louai Manini; Michael Camilleri; Rayna Grothe; Carlo Di Lorenzo
Journal:  Paediatr Drugs       Date:  2018-04       Impact factor: 3.022

Review 6.  Recent Advances in the Management of Severe Gastrointestinal Dysmotility.

Authors:  Dipesh H Vasant; Simon Lal
Journal:  Clin Exp Gastroenterol       Date:  2021-05-10

7.  Chronic intestinal pseudo-obstruction associated with enteric ganglionitis in a Persian cat.

Authors:  Jeremy Mortier; Estelle Elissalt; Sophie Palierne; Marie Odile Semin; Maxence Delverdier; Armelle Diquélou
Journal:  JFMS Open Rep       Date:  2016-06-14

8.  Cholinergic interactions between donepezil and prucalopride in human colon: potential to treat severe intestinal dysmotility.

Authors:  J Broad; V W S Kung; G Boundouki; Q Aziz; J H De Maeyer; C H Knowles; G J Sanger
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

9.  Patients with Specific Gastrointestinal Motility Disorders are Commonly Diagnosed as Functional GI Disorders in the Early Stage by Community Physicians due to Lack of Awareness.

Authors:  Uday C Ghoshal; Bhavesh Bhut; Asha Misra
Journal:  Turk J Gastroenterol       Date:  2021-04       Impact factor: 1.852

10.  Comparison of pyridostigmine and bisacodyl in the treatment of refractory chronic constipation.

Authors:  Iman Soufi-Afshar; Aliakbar Moghadamnia; Ali Bijani; Sohrab Kazemi; Javad Shokri-Shirvani
Journal:  Caspian J Intern Med       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.